BioXell S.p.A.
http://www.bioxell.com/index.lbl
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioXell S.p.A.
ADC Competition Heats Up In China But Caution, Pressure Also Mount
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
Earlier-Stage Approvals For Tecentriq, Keytruda, Verzenio Underscore Broader Oncology Trends
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Scottish Funding Wins for Kite’s CAR-T Tecartus & Five Other Products
A total of six medicines were recommended for use on the National Health Service in Scotland in August.
Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility
Proposed reimbursement decision to be released by 12 January 2022, with a final decision the following April. Biogen's Aduhelm expected to be covered in the interim. Medicare will not consider the cost of treatment in the analysis, but cost may have been a factor in initiating the process.